ProMIS Neurosciences Inc.【PMN】

時価総額

$4983.8万

PER

神経変性疾患向け治療薬開発の新興企業。PMN310を含む抗アミロイド抗体と診断技術を展開。2024年7月29日のPIPEで約2,770万ドルを調達、2024年12月31日時点で現金1,330万ドル保有、2022年6月28日に60:1の逆株式分割を実施。トロント本社、NASDAQ上場で北米中心展開。

	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss)	-18,062,263	-13,212,482	3
Share-based compensation	487,630	271,542	825,808
Foreign currency exchange gain	-305,407	1,817	-
Loss on Sale of Common Shares and Warrants	-	-	4
Change in fair value of financial instruments	3	-	23
Depreciation	6,144	321	-
Amortization of intangible assets	5,072	20,838	-
Prepaid expenses and other current assets	318,747	187,321	5
Accounts payable	3	5	-6,105,673
Accrued liabilities	3	-1,831,237	-1,025,564
Net cash used in operating activities	-17,033,883	-10,843,676	-27,182,095
Purchase of short-term investments	31,009	32,358	33,051
Maturity of short-term investment	31,009	31,009	32,358
Net cash used in investing activities	-1,981	-1,349	-693
Proceeds from Issuance of Common Stock	5	-	190,274
Proceeds from Issuance of Warrants	2	-	-
Net Proceeds From Issuance Of Common Stock And Warrants	-	18	28
Proceeds from Warrant Exercises	-	3,600	28,038
Net cash provided by financing activities	6	18	28
Effect of exchange rates on cash	-526,899	-181,425	-
Net increase in cash	-11,068,109	7	693,021
Deferred Issuance Cost Included in Accounts Payable and Accrued Liabilities	-	195,362	-
Issuance Of Compensation Warrants In Consideration Of Issuance Costs	343,000	466,658	-
Reclassification Of Warrants From Equity To Liability	-	-396,375	-
Reclassification Of Warrants From Liability To Equity	-	1	-
Reclassification Of Pipe Warrants From Liability To Equity	-	-	9
Decrease in Additional Paid in Capital For Share Based Compensation Liability	-	681,308	222,739
Cash paid for interest	87,069	-	76,775